Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
about
Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatasesIL-2 mediates CD4+ T cell help in the breakdown of memory-like CD8+ T cell tolerance under lymphopenic conditionsPathway-based analysis of a melanoma genome-wide association study: analysis of genes related to tumour-immunosuppressionImmune surveillance of tumors.Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapyAiming to immune elimination of ovarian cancer stem cellsTumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.Lessons from cancer immunoediting in cutaneous melanoma.CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy.Overall survival and PD-L1 expression in metastasized malignant melanoma.Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity.Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.Melanoma vaccines: prospects for the treatment of melanoma.Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.Multi-epitope DNA vaccines.
P2860
Q28263470-3FE24A18-BD4F-4EA3-AD15-DA836B6236A5Q33697777-D9EF7463-4665-4FEA-9E85-CB8A9FF8D956Q34117595-F5B11F26-150D-424D-AFB1-F0C6A95342AEQ34579196-7A81FF54-DE29-431C-A3B9-2DA72192A333Q36366583-02999447-168D-4C60-A82A-BF0D246C2B57Q36954938-09E3B6AB-716E-47FB-BCA2-F2A4B6265C9FQ37266548-21E7D962-218D-40BE-ACEC-5D30DBBB267BQ37360526-09B14F57-2433-419F-8E36-28587B217D1AQ38038176-A767E6FD-0789-4437-B496-352B3BFD9C05Q39541849-D9D71DA3-783E-4F73-9F57-AF742D326DFFQ39756798-F0269991-C258-4451-A6A2-0B94EBF09F32Q39870340-BB4B4997-3EF4-43BB-81FC-506AF813813DQ40849487-4963E671-EDEC-40F6-89E0-F818BBAD6ED1Q40900776-80277F0F-67A6-497D-88BB-5ADC49A7238DQ40913310-22059DF9-ED12-4BE3-B7D6-E51BA83F371FQ41604754-77E7E535-26F8-4F55-801E-864147FE75DD
P2860
Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Defective lymphokine productio ...... tologous tumor cells in vitro.
@en
Defective lymphokine productio ...... tologous tumor cells in vitro.
@nl
type
label
Defective lymphokine productio ...... tologous tumor cells in vitro.
@en
Defective lymphokine productio ...... tologous tumor cells in vitro.
@nl
prefLabel
Defective lymphokine productio ...... tologous tumor cells in vitro.
@en
Defective lymphokine productio ...... tologous tumor cells in vitro.
@nl
P2093
P356
P1476
Defective lymphokine productio ...... utologous tumor cells in vitro
@en
P2093
Guilloux Y
Jotereau F
Le Dréan E
Pandolfino MC
P304
P356
10.1002/EJI.1830240905
P407
P577
1994-09-01T00:00:00Z